Be it here in Australia, or in the US, doctors are the ones who make decisions on prescriptions, based on their professional judgement. This includes off-label prescription.
However, it is not doctors who are the main barrier to off-label access; it is the payers, especially in the case of high-priced drugs. Most insurance companies will not provide reimbursement for high-priced drugs in non-approved indications.
While we don’t know how trofinetide will be priced, it is likely to be unaffordable for most people if it’s not covered by insurance.
Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-24
-
- There are more pages in this discussion • 140 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.622B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1024 | $20.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.53 | 285 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |